Smruthi Organics Gets "Attestation of Inspection" from European Regulator after Solapur, India Unit Inspection

MT Newswires Live
03/04

Smruthi Organics (BOM:540686) has received an "attestation of inspection" from the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, after the inspection of its active pharmaceutical ingredient (API) manufacturing facility, Unit II in Solapur in Maharashtra, India.

The regulator had inspected the Solar unit from Aug. 27, 2025, to Aug. 29, 2025, and the attestation marks the closure of the EDQM inspection process, according to a BSE filing on Wednesday.

The company said the positive inspection outcome is expected to support its business expansion, improve customer confidence, and create additional opportunities in regulated export markets.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10